Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Janet Retseck PhD, MD

Janet Retseck PhD, MD profile photo picture

Assistant Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Medicine Hematology Oncology

View Curriculum Vitae

Publications (9)

  • Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy. (Patel R, Weil E, Bugamelli S, Carroll E, Steinke K, Stockhausen E, Burfeind J, Mooney C, Retseck J, Sriram D, Deininger J, Halbach A, Sweeney M, Kamaraju S, Chaudhary LN, Cheng YC) Breast Cancer Res 2025 Aug 18;27(1):147 PMID: 40826432 PMCID: PMC12360005 SCOPUS ID: 2-s2.0-105013522509 08/19/2025       5 Citations
  • High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab (Ellison C, Martens M, Alvarez Argote J, Benz S, Currey A, Johnstone C, Klawikowski S, Livingston K, Longo JM, Menon S, Ortiz de Choudens S, Puckett L, Retseck J, Shukla M, Thompson J, Gore E) Jto Clinical and Research Reports December 2024;5(12) SCOPUS ID: 2-s2.0-85207777055 12/01/2024       3 Citations
  • Matched Case Control Analysis of Breast Cancer- Specific Factors Affecting Risk of Developing SARS-CoV-2 Infection. (Pierro M, Zurko J, Szabo A, Cheng YC, Kamaraju S, Burfeind J, Retseck J, Chitambar CR, Chaudhary LN) WMJ 2023 Dec;122(5):418-421 PMID: 38180937 SCOPUS ID: 2-s2.0-85181850540 01/05/2024       1 Citation
  • When the Future Is Not Now. (Retseck J) J Clin Oncol 2023 Oct 01;41(28):4592-4594 PMID: 37552827 SCOPUS ID: 2-s2.0-85174642358 08/08/2023       18 Citations
  • High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab. (Ellison C, Martens M, Alvarez Argote J, Benz S, Currey A, Johnstone C, Klawikowski S, Livingston K, Longo JM, Menon S, Ortiz de Choudens S, Puckett L, Retseck J, Shukla M, Thompson J, Gore E) JTO Clin Res Rep 2024 Dec;5(12):100537 PMID: 39555223 PMCID: PMC11567112 SCOPUS ID: 2-s2.0-85207777055 06/15/2023       3 Citations
  • Leveraging Social Determinants of Health to Reduce Hospital Length of Stay: A Pilot QI Project for Solid Tumor Oncology Patients During the COVID-19 Pandemic. (Kamaraju T, Atkinson D, Wright T, Charlosn J, Wetzel T, Campbell G, Cadman J, Williams J, Egede L, Retseck J, Banerjee A, Ehrlich V, Stolley M, Power S) WMJ 2022 Oct;121(3):205-211 PMID: 36301647 SCOPUS ID: 2-s2.0-85140859344 10/28/2022       4 Citations
  • Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. (Retseck J, Nasr A, Lin Y, Lin H, Mendiratta P, Butterfield LH, Tarhini AA) J Transl Med 2018 Jul 04;16(1):184 PMID: 29973204 PMCID: PMC6033230 SCOPUS ID: 2-s2.0-85049518171 07/06/2018       48 Citations
  • Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. (Retseck J, VanderWeele R, Lin HM, Lin Y, Butterfield LH, Tarhini AA) J Immunother Cancer 2016;4:38 PMID: 27330811 PMCID: PMC4915044 SCOPUS ID: 2-s2.0-84997327284 06/23/2016       21 Citations
  • Treatment response to transcatheter arterial embolization and chemoembolization in primary and metastatic tumors of the liver. (Artinyan A, Nelson R, Soriano P, Chung V, Retseck J, Reynolds J, Marx H, Kim J, Wagman L) HPB (Oxford) 2008;10(6):396-404 PMID: 19088924 PMCID: PMC2597318 SCOPUS ID: 2-s2.0-57049136773 12/18/2008       21 Citations
    • Last update: 12/08/2025